key: cord-0872365-qfitmkui
authors: Ahn, Hongshik; Jiang, Haoran; Li, Xiaolin
title: Modeling and computation of multistep batch testing for infectious diseases
date: 2021-04-19
journal: Biom J
DOI: 10.1002/bimj.202000240
sha: 6d9221fe4a97ab6d855a24f3f8228a9cb7360f91
doc_id: 872365
cord_uid: qfitmkui

We propose a mathematical model based on probability theory to optimize COVID‐19 testing by a multistep batch testing approach with variable batch sizes. This model and simulation tool dramatically increase the efficiency and efficacy of the tests in a large population at a low cost, particularly when the infection rate is low. The proposed method combines statistical modeling with numerical methods to solve nonlinear equations and obtain optimal batch sizes at each step of tests, with the flexibility to incorporate geographic and demographic information. In theory, this method substantially improves the false positive rate and positive predictive value as well. We also conducted a Monte Carlo simulation to verify this theory. Our simulation results show that our method significantly reduces the false negative rate. More accurate assessment can be made if the dilution effect or other practical factors are taken into consideration. The proposed method will be particularly useful for the early detection of infectious diseases and prevention of future pandemics. The proposed work will have broader impacts on medical testing for contagious diseases in general.

To fight the COVID-19 pandemic with limited resources, batch tests were recommended by pooling multiple swab samples. Samples from different individuals are pooled into one batch and then a high-throughput PCR test is conducted (Cheng, 2020; Lohse et al., 2020; Shani-Narkiss et al., 2020) . If the batch is tested negative, then it can be deduced that all samples were negative. Otherwise, each sample needs to be tested individually. Pooling data was originally proposed by Dorfman (1943) for detecting syphilis in U.S. soldiers during World War II. France et al. (2015) used pooling samples to reduce the number of analyses required for detection of anthrax spores. By grouping individual samples, batch testing significantly reduces the number of tests, providing an efficient method to detect community transmission (Hogan et al., 2020) . Batch testing has become more relevant recently, as state and local governments seek to test as many people as possible to transition safely back to normal life. For example, a recent press release by the U.S. Food and Drug Administration (FDA) indicates developers' interest in incorporating pooling samples for domestic testing (Shuren, 2020) . Places abroad such as South Korea started using pooling methods to sample in batches of a fixed size in high-risk communities (Korea Center for Disease Control & Prevention, 2020; Kwak, 2020; Park & Koo, 2020) . However, the drawback to batch testing is a much higher false negative rate than individual testing.

In this study, we introduce a batch-based approach, which simultaneously addresses the problem of limited resources and testing accuracy. We consider a multistep testing procedure with variable batch sizes where each step divides the population into subpopulations based on the previous step's results. These subpopulations are further divided into batches for testing. We introduce a method to estimate the optimal batch sizes given the infection rates of subpopulations to efficiently and accurately test most, if not the entire, population. The proposed method incorporates testing errors and optimizes batch sizes at each step and for each subpopulation. Shani-Narkiss et al. (2020) also considered a multistep testing procedure with variable batch sizes. However, their approach assumes no testing errors, and their batch sizes are limited to powers of two.

For batch testing, typically a sample from each person is divided into multiple aliquots for separate tests (Mutesa et al., 2020) . The population is split into subpopulations with negative test results (batch negative) and positive test results (batch positive). Each subpopulation is given another round of batch tests where the batch size increases for the batch negatives and decreases for the batch positives. We iterate this procedure on each subpopulation, where at each step we can estimate the infection rate. This process is continued until one of the following conditions is satisfied: (i) The process results in three batch negatives or three batch positives, (ii) the infection rate of the subpopulation becomes higher than 30%, and (iii) the optimal batch size is reduced to 2. The samples are randomly assigned to different batches with the size determined by the infection rate in each round. Details of this procedure are given in Section 2.5. To apply our approach most effectively, we can first divide the population based on infection rates, for example, by dividing based on geography, population density, proximity to highly infected regions, etc. Information given by various methods including mobile apps and online mapping (Lee & Lee, 2020) may help track the virus and divide the population into different groups.

We also address the efficacy of the tests. The false negative rate of the COVID-19 polymerase chain reaction (PCR) test for an individual is known to be near 15%, ranging from 10% to 30% (West et al., 2020; Xiao et al., 2020; Yang and Yan, 2020) . By one-step batch testing, the false negative rate increases (Shuren, 2020) . By our multistep batch testing procedure, the false negative rate is substantially reduced. To the best of our knowledge, no other studies have attempted estimating optimal batch sizes by taking testing errors into account. The dilution effect in batch testing (Hwang, 1976; McMahan et al., 2013; Yelin et al., 2020) is not considered in this study. The false negative rate may be increased by the dilution effect.

If three batch negatives occur before getting three batch positives, then we conclude that the individuals in the batch of the final round are not infected. For people whose samples result in three batch positives before three batch negatives, each sample needs to be tested individually to find out which was positive. To reduce the false negative rate, up to three individual tests are performed for the samples from each individual in this group. For a population of size 100,000 with an infection rate of 0.1%, if the false negative rate is 15% and false positive rate is 1% for an individual test, then our method requires around 7000 tests to test the entire population. Results for different infection rates are detailed in Section 3. The simulation results show that our method reduces the false negative rate to approximately 3%, and the false positive rate to near zero.

It is a well-known fact that the positive predictive value (PPV) is very low when the infection rate is low even if the sensitivity is very high. For a false positive rate of 1% and false negative rate of 15%, the PPV of an individual test is 8% for an infection rate of 0.1%, and 46% for an infection rate of 1%. According to our simulation, our multistep batch testing procedure improves the PPV to 89% and 93%, respectively. This is because individual tests are conducted on the subject in the final positive batches, which have higher infection rates than the entire population (see Section 2.4 and Section 3).

The proposed batch testing procedure is compared with matrix pool testing as well as single batch testing with fixed or variable batch sizes. Two-dimensional pooling strategy has been studied by researchers including Barillot et al. (1991) , Amemiya et al. (1992) , Phatarfod & Sudbury (1994) , and Hudgens and Kim (2011) . The false negative rate decreases to 1% if 12 × 12 matrix pool tests are conducted three times parallel with up to three sequential individual tests to all the positive crossings. However, the number of tests to cover the whole population is much more than that of the proposed multistep batch testing procedure, and it is more than a half the population size even when the infection rate of the population is 0.1% (see Section 3).

The original purpose for batch testing was to prevent the spread of disease in high-risk communities by testing everyone, symptomatic or not. However, the proposed method can be applied to the general population, due to its flexibility in dealing with various infection rates and its substantially greater sensitivity compared to individual testing and current batch testing approaches. More specifically, our method can accurately test a large population with limited resources by dividing the population based on infection rates, for example, based on geography, population density, proximity to highly infected regions, etc. This method can be applied to effectively combat a future pandemic of new diseases.

We begin by studying a simple case where the accuracy of a virus screening test is 100%. Suppose that the infection rate in a population is (rate of no infection is = 1 − ) and the accuracy of a virus screening test is 100%. Let be a random variable denoting the number of positive cases in a batch of size . Then, follows a binomial distribution with trials and success rate . The probability of positive cases in the batch is

and the probability that the batch is tested negative is ( = 0) = (1 − ) = .

Using an initial guess of the batch size , we want to estimate . Let = ( = 0). Then after a good number of batch tests, we can estimate by

Suppose we test a population in batches of size , then test all individuals who were in positively tested batches. For a population of size , the expected total number of tests to be performed to identify all positive carriers is

To find the optimal , we minimize ( ) as

We can solve this equation for numerically.

We conduct a hypothesis testing with null hypothesis 0 : The subject is uninfected versus alternative hypothesis 1 : The subject is infected. To reduce testing errors, we propose a procedure of conducting multiple rounds of batch tests before carrying out individual tests for a selected group. Denote the probability of a type I error (false positive rate) as and the probability of a type II error (false negative rate) as . Let the infection rate be 1 and 1 = 1 − 1 in the initial batch tests for the whole population, and the random variable denoting the number of positive cases in a batch of size 1 . Then, the probability of a batch negative based on (1) can be obtained as

Using an initial guess of the batch size 1 , we want to estimate 1 . After a good number of batch tests, we can estimate 1 by Suppose all the subjects in the positive batches get individual PCR tests. If the size of the entire population is 1 , the required number of tests can be obtained from (2) by substituting (3) for as

To find the optimal batch size , we minimize 1 ( ) as

This can be solved for numerically. In this study, we used the secant method to solve the equation. The optimal batch size 1 is either floor( ) or ceiling( ), which has the lower value of (⋅). For example, when the infection rate is 1% ( = 0.99), = 0.01, and = 0.15, the solution of (6) is = 11.53. We need an integer 1 minimizing the convex function 1 ( 1 ) in (5), which is adjacent to 11.53. Since 1 (11) = 0.18883 × 1 and 1 (12) = 0.18877 × 1 , the solution is 1 = 12 as shown in Table 1 . The initial batch tests can be conducted using 1 for the whole population.

Continuing this process, after the ( − 1)th round, the subjects have been divided into subpopulations. Each subpopulation was batch tested with batch sizes determined from that round. Fixing one of these subpopulations, we now split it into two smaller subpopulations for the th round, according to the batch test results from the ( − 1)th round. Let denote the number of subjects in population belonging to test-negative batches from the ( − 1)th round, and denote the infection rate of this subpopulation. The expected size of the subpopulation in the th round of batch tests is

In this subpopulation, the probability that at least one subject in a batch is infected is

and the probability that all the subjects in a batch are not infected is 1 − . The estimated number of infected subjects in this subpopulation is

Here, E( −1 )∕ ( −1 > 0) is the expected number of infected subjects in a test-positive batch in the ( − 1)th round, where −1 is a binomial random variable with −1 trials and success rate −1 . Therefore, the infection rate of the subpopulation in the th round can be used for estimating the optimal batch size and the required number of tests. The optimal number of required tests can be obtained by replacing 1 with and 1 with in (3) and (5) to get

and the optimal batch size for this round is obtained by minimizing (⋅). For example, suppose the estimated infection rate is 1 = 0.01 and = 0.01, = 0.15 for the population of size 100,000. Then 1 ( ) in (5) is minimized when 1 = 12. For the second round, the expected subpopulation size is obtained from (7) For this infection rate, the optimal batch size 2 = 27 is obtained by minimizing 2 ( ) in (10). These numbers can be found in the second part of Table 5 under Round 2.

Further, we can estimate the optimal batch size for the subpopulation consisting of batch positives. In the ( − 1)th round, the probability that a batch of size −1 is tested positive is

The size of this subpopulation can be modified from (7) as

In this subpopulation, the probability that at least one subject in a batch is infected is

and the probability that all the subjects are not infected is 1 − . The estimated infection rate in this subpopulation can be obtained as (9). This infection rate can be used for estimating the optimal batch size and the required number of tests for the subpopulation in the th round. The accuracy of these formulae developed in this section has been confirmed by matching results with the simulation results given in Section 3. Figure 1 displays the optimal batch size and the required number of batches for a population of size 100,000 as the infection rate ranges from 0.001 to 0.25 for the first round, and the false negative rate ranges from 0.1 to 0.25. The false positive rate is fixed at 0.01. Table 1 displays the optimal batch sizes for different infection rates (a) when no testing errors are assumed and (b) when the false negative rate is 15% and the false positive rate is 1%. TA B L E 2 Probability in each cell of the confusion matrix for single batch testing

Test − (a) (1 − ) ( = 0) (b) ( > 0) Result + (c) ( = 0) (d) (1 − ) ( > 0)

Let us consider one-step batch testing. If a batch is tested negative, then we conclude that all samples in the batch are negative. If a batch is tested positive, then each sample in the batch needs to be tested individually. Let the binomial random variable denote the number of positive cases for a batch of size with an infection rate of . We continue to denote as the probability of a type I error and as the probability of a type II error for an individual test. Table 2 displays the probabilities for the confusion matrix.

In cells (b) and (d), at least one sample is infected in each batch. It can be deduced that all the samples in cell (b) are negative, and no more tests are given. The probability that an infected individual is incorrectly tested negative from the batch test is

In cell (d), the probability that an infected individual is correctly tested positive from the batch test is

An individual test is given to each sample in this cell, and the probability that a sample is incorrectly tested negative is (1 − ) ( > 0)[ ∕ ( > 0)] = (1 − ) . Therefore, the false negative rate is obtained as

For example, if = 0.15, then the false negative rate of batch testing is 0.15(2 − 0.15) = 0.2775, and thus the sensitivity is 0.7225. For = 0.1, 0.2, and 0.25, the sensitivity of batch testing is 0.81, 0.64, and 0.5625, respectively. Note that the sensitivity of a batch test depends on neither the infection rate nor the batch size. The above result is supported by our simulation given in Section 3. It confirms that the sensitivity is decreased by conventional batch testing. In contrast, our multistep batch testing method has a significantly higher sensitivity than conventional individual tests as well as single batch testing according to our simulation studies.

The false positive error occurs in cells (c) and possibly in (d) in Table 2 , and all the samples in these cells go through individual tests. In cell (c), the probability that a sample is incorrectly tested positive in the individual tests is

In cell (d), the expected infection rate in each batch is ∕ ( > 0). The probability that an uninfected sample is incorrectly tested positive in the individual tests in this cell is

The sum of (11) and (12) is

TA B L E 3 Specificity for single batch testing with fixed batch size of 10 and optimal batch size for the false positive rate of 0.01, 0.03, and the false negative rate of 0. Therefore, the false positive rate of batch testing is

and the specificity of batch testing is

Unlike the sensitivity of batch testing, the batch size, infection rate, probability of a type I error, and probability of a type II error contribute to (13). For = 0.01 and 0.03, and = 0.1, 0.15, 0.2 and 0.25, the specificity of batch testing (13) using a fixed batch size of 10, and using the optimal batch size is given in Table 3 . The specificity is substantially improved by batch testing. These results closely match with our simulation results given in Section 3.

Let us define as the event that an individual is infected by the virus, and as the event that an individual got a positive test result. Then by the Bayes' rule, PPV (an individual is infected given a positive test result) is and NPV (negative predictive value: an individual is not infected given a negative test result) is

For example, if the infection rate in the population is 1%, sensitivity is 85%, and specificity is 99%, then ( ) = 0.01, ( | ) = 0.85 and ( | ) = 0.99. Therefore, the PPV is 0.4620 and the NPV is 0.9985. If the infection rate is 0.1%, then the PPV is 0.0078 and the NPV is 0.9998. For the infection rates ∈ [0.001, 0.2], sensitivity within the range of [0.75, 0.90] and the specificity of 0.99, Table 4 illustrates PPV and NPV. Figure 2 displays the PPV (above) and NPV (below). The PPV is substantially improved by our multistep batch testing procedure (see Section 3).

More than three batch negatives may not be necessary in the procedure because the infection rate substantially decreases in later rounds. Figure 3 illustrates the proposed batch test procedure. We will further investigate the optimal number of batch tests and the stopping rule in this study. For batch negatives, the batch size increases substantially with most of the subjects remaining in the next round because the infection rate decreases. For batch positives, the subpopulation F I G U R E 2 PPV (above) and NPV (below) size substantially decreases in the next round. In this group, not all the samples in the batch are infected, so we can find a sample without infection in the next round of batch tests. This way, the number of required tests to cover the whole population decreases significantly, and it is possible to identify all positive carriers in the population. We assume 15% false negative rate and 1% false positive rate of an individual for a population of size 100,000 in this section. Table 5 shows the change in the infection rate and corresponding optimal batch size throughout the process shown in Figure 3 for a population with infection rates of 0.1% and 1%. In the first round, the optimal batch size is 35 resulting in 2858 batch tests when the infection rate is 0.1%, and the optimal batch size is 12 resulting in 8334 batch tests when the infection rate is 1%. Note that the number of batch tests for the first round can be slightly different from this estimation due to the trial for estimating the infection rate with (4) using a small subset of the population with an initial guess of the batch size. The subsequent rounds do not require this trial because the infection rates of subpopulations can be estimated as (9) using the values obtained in the previous rounds. For the th round, the number of batch tests can be obtained by ceiling( ∕ ). We count only the bold-faced numbers starting the first round because the rest are duplicates. In each of Round 2 and Round 3, the bold-faced subpopulation sizes ( ) add up to 100,000 if we ignore the TA B L E 5 Batch test procedure: population size 100,000, false negative rate 15% and false positive rate 1% for individual tests, infection rates 0.1% and 1% Table 5 . For the infection rate of 0.1%, the expected number of infected cases among the samples who received individual tests at the end of the procedure is 97.8 out of 448. With the 85% sensitivity for individual tests, the sensitivity of this procedure is 83.1% since 97.8 × 0.85 = 83.1 out of 100. For the infection rate of 1%, the expected number of infected cases among the samples who received individual tests is 975.5 out of 3027. The sensitivity of this procedure is 82.9% since 975.5 × 0.85 = 829 out of 1000. To calculate the specificity, for the infection rate of 0.1%, the expected number of uninfected samples among the samples who received individual tests is 350.2 out of 448. With the 1% type I error rate for individual tests, since 350.2 × 0.01 = 3.502, the specificity of this procedure is 100[1 − (3502∕99, 900)]% = 99.996%. For the infection rate of 1%, the expected number of uninfected samples among the samples who received individual tests is 2051.5 out of 3027. Since 2051.5 × 0.01 = 20.515, the specificity of this procedure is 100[1 − (20.515∕99, 000)]% = 99.98%. These results closely match with our simulation results given for method (E) in Table 7 of Section 3.

To reduce the false negative rate, we propose to conduct sequential individual tests as follows: We conduct up to three tests for the same person sequentially until a positive test occurs. Let us define as the event that an individual is infected by the virus, and as the event that an individual got a positive result in the th individual test. Then, the probability that a sample is tested positive in the first test is

the probability that a person is tested negative and then tested positive is

and a person is tested negative twice is 

Thus, the expected number of the individual tests for each person is 1 + 2 2 + 3 3 .

We can obtain the expected total number of sequential individual tests by substituting the infection rate and the subpopulation size in each of the bottom 10 rows of the last two columns in Table 5 . For the infection rate of 0.1%, the expected number of sequential individual tests in (14) Table 7 of Section 3. To further illustrate how the false negative rate is reduced by this procedure, Table 6 lists all possible cases shown in Table 5 with the false negative rate in each case. Among the 20 possible cases of batch testing, the first 10 cases result in 3 batch negatives, and the second 10 cases result in 3 batch positives. If a sample is in one of the first 10 cases, then it will be deduced as uninfected, and if it is in one of the second 10 cases, then it requires up to 3 sequential individual tests. The false negative rate is 3 = 0.003375 for Case (1) because it has three batch negatives, (1 − ) 3 = 0.00287 for Cases (2) through (4) because it has three batch negatives and one batch positive, and (1 − ) 2 3 = 0.00244 for Cases (5) through (10) because it has three batch negatives and two batch positives. Since false negative occurs when a sample gets negative in all three individual tests sequentially, 3 is multiplied by the rates given in Table 6 to the second 10 cases. The false negative rate is (1 − ) 3 3 = 0.00207 for Case (11), (1 − ) 3 4 = 0.00031 for Cases (12) through (14), and (1 − ) 3 5 = 0.000047 for Cases (15) through (20). An estimation of the false negative rate of the proposed batch testing procedure can be obtained by multiplying the false negative rate with the subpopulation size given in the last column of Table 5 in each case and divide the sum of these 20 numbers by 100,000. The estimated false negative rate is 3.33% when the infection rate is 0.1%, and 3.25% when the infection rate is 1%. These results yield the sensitivity of 96.67% and 96.75%, respectively. These estimates of the sensitivity are slightly lower and the estimates by combining groups of 10 cases in the previous paragraph (97.5% and 97.2%, respectively) are slightly higher than the simulation results for method (F) in Table 7 given in Section 3, but they are within one standard deviation (1.65% for infection rate 0.1% and 0.57% for infection rate 1%).

Simulation results: 100 repetitions, population size 100,000, sensitivity 85% and specificity 99% for individual tests; mean with standard deviation in parentheses ( ) 

We conducted a Monte Carlo simulation study to evaluate the efficiency and efficacy of the proposed batch testing procedure. In this simulation, we assume that the sensitivity and specificity of individual tests are 85% and 99%, respectively. A population of 100,000 people is randomly generated 100 times. The infection rates of 0.1%, 1%, 3%, 5%, and 10% are chosen. Table 7 compares our methods with conventional individual tests, single batch tests, and matrix pool tests using various accuracy measures. We compare the accuracy measures for (A) conventional individual tests, (B) one-step batch testing with a fixed batch size of 10, (C) one-step batch testing with optimal batch sizes, with up to three sequential individual tests for each of the positive batches, (D) parallel 12 × 12 matrix pool testing (to cover the whole population, 694 12 × 12 matrices and one 8 × 8 matrix are used); up to three sequential individual tests for all the positive intersections. Since a single matrix testing gives very low sensitivity, we report results from three parallel matrix pool tests. (E) proposed multistep batch tests ending with three batch negatives or three batch positives, with an individual test given to three batch positives, (F) multistep batch tests given in (E), with up to three sequential individual tests for three batch positives. For (C), (E), and (F), the optimal batch sizes estimated in Section 2.5 are used in the subpopulations in each step. For each of the infection rates, the overall accuracy, sensitivity, specificity, PPV, and NPV are calculated, and the required number of tests to cover the whole population is calculated from this simulation, and the values are averaged over the 100 repetitions. The fixed batch size of 10 given in (B) has been used in South Korea for high-risk facilities. For multistep batch testing, individual tests are conducted to the subpopulation if the infection rate exceeds 30% in any step as mentioned in Section 1. Another set of simulation results for sensitivity of 75% and specificity of 97% is given in the Appendix. The comparison between our methods and the conventional individual tests, single batch testing, or matrix pool tests gives a similar pattern to the one given in this section. For the matrix pool testing, we also simulated conventional one-step matrix pool test with an individual test to the positive intersection, but the sensitivity was less than 62% for all the infection rates. For one-step matrix pool tests with up to three sequential tests to each of the positive intersection, the sensitivity was around 72%. For three parallel matrix pool tests with an individual test to all positive intersections, the sensitivity was around 84%. To achieve high performance for the comparison, we report simulation results for three parallel matrix pool tests with up to three sequential individual tests to all positive intersections in (D). Although not reported in this paper, single-step batch testing with variable batch sizes also was conducted. The accuracy measures were very close to those of the fixed batch size in (B). However, the batch tests with variable batch sizes require fewer tests.

Note that the number of required tests in the proposed method (F) is close to the estimated number derived in Section 2.5. The sensitivity is reduced in the one-step batch tests (given in (B)) to approximately 72% from conventional individual tests. This is because if a batch is tested negative, then all the samples in the batch are considered uninfected, and no further tests are given. The results are in line with the sensitivity of 72.25% for one-step batch testing obtained in Section 2.3.1. Method (C) substantially improved the sensitivity to almost the same level as the sensitivity of conventional individual tests. The sensitivity of method (E) is around 83%, and it is improved by method (F) to approximately 97%. These results show that both the multistep batch testing and sequential individual tests significantly improve the sensitivity. These are in line with the numbers obtained from the model in Section 2.5. This improvement is achieved because sequential individual tests are given to small target subpopulations obtained by our test procedure. Although not included in Table 7 , we also conducted a simulation of multistep batch testing with a fixed batch size of 10 followed by up to 3 sequential individual tests. The sensitivity of this method was almost identical to that of method (F) because the sensitivity does not depend on the batch size. However, method (F) requires much fewer tests by using the optimal batch sizes (7053 for method (F) vs. 32,118 for a fixed batch size for infection rate 0.1%, and 27,809 for method (F) vs. 46,416 for a fixed batch size for infection rate 1%). The sensitivity of method (D) is around 99%. However, the number of tests for matrix pool testing is 50,727 for the infection rate of 0.1% and 56,201 for the infection rate of 1%. Although not included in the simulation table, we also simulated three parallel batch testing with a fixed batch size of 10. The sensitivity of the method was near 85%, and the number of tests to cover the whole population was slightly over 30,000 which is larger than that of method (F) for infection rates of 0.1% or 1%, but fewer for the infection rates higher than 1%. The sensitivity of this parallel batch testing was much lower than that of method (F).

As mentioned in Section 2.3.2, the specificity is significantly improved by batch testing from conventional individual testing. The specificity of single batch testing obtained in this simulation closely matches with the expected value given in (13). See also Table 3 . Although the specificity of the batch tests decreases as the infection rate increases, the onedimensional batch tests (B, C, E, and F) have much higher specificity than the baseline of 99% for all infection rates in Table 7 . However, the specificity of the matrix pool tests decreases fast as the infection rate increases and it becomes lower than 99% for the infection rate of 10%.

The improvement of the PPV by our procedure is remarkable. As discussed in Section 2.4 (also shown in (A) of Table 7) , the PPV of an individual test is 8% and 46% when the infection rates are 0.1% and 1%, respectively. According to our simulation, single-step batch testing in (B) improves this to 81% and 90%, respectively, and it is further improved by multistep batch testing given in (E) to 95% and 97%, respectively. The PPV is decreased by sequential individual tests. It is 43% and 75%, respectively, in (C). However, it is improved to 88.5% and 93%, respectively, in (F) by multi-step batch testing. The PPV is 94% and 95%, respectively, for the matrix pool tests in (D).

The overall number of batch tests from the simulation is close to the estimated number from our model given in Section 2.2. For 0.1% infection rate, the number of multistep batch tests in the simulation (methods (E) and (F)) is around 5700 and the estimated number is 5696. For 1% infection rate, the number is around 19,440 from the simulation and 19,409 from our estimation. However, the simulated number of individual tests for samples with three batch positives is slightly higher than the predicted value. This is likely due to randomness. This discrepancy does not significantly impact the overall number of tests because the size of the subpopulation requiring individual tests is very small (approximately 0.5% for 0.1% infection rate, and around 3% for 1% infection rate) compared to the whole population. For 0.1% infection rate, for example, 516 people received individual tests in the simulation (given in (E)), whereas the model estimates that 448 people need individual tests. This means approximately 99.5% of the population do not require individual tests. The model estimate of this value is 99.552% (100, 000 − 448), and the simulated value is 99.484% (100, 000 − 516).

Note that the overall accuracy is mostly affected by specificity because the infection rates are low. We can incorporate geographic and demographic information for more realistic calculation.

The COVID-19 pandemic changed our lifestyle, seriously impacted the global economy, and took many precious lives. To get back to normalcy, we need a rapid testing of the virus for all the residents of each community. Unlike other coronavirus outbreaks we experienced in the past, the disease rapidly spreads silently by asymptomatic carriers. Since only patients with symptoms have been getting tests, it is a challenging task to identify asymptomatic COVID-19 carriers. In most countries including the United States, some patients with symptoms could not get tests due to the limited testing capacity. To conduct testing a broader population more efficiently, batch testing methods have been introduced. The South Korean Center for Disease Control & Prevention used a single-step batch testing for long-term care facilities with a fixed batch size of 10 for the entire staff and patients. As seen in our simulation studies, batch testing increases the false negative rate, although this approach can monitor high-risk groups without symptoms by reducing the number of tests needed to cover the entire community. In this paper, we proposed a multistep batch testing procedure to substantially decrease the false negative rate using a small number of test kits to completely test a large population. The improvement of PPV from individual testing is also remarkable, thus our multistep approach can be trusted for reliable results.

Our approach will be useful for the prevention for early stages of future pandemics. Our method is most effective for diseases with infection rates of up to 3%. We do not recommend this approach for highly contagious large populations with infection rates greater than 5%, as the prescribed amount of tests becomes very large. In contrast, our method is also useful for moderate size, highly contagious communities, which require accurate virus screening for the entire community. Shuren (2020) addresses that conventional batch testing has a higher chance of false negative results because samples are diluted, but it works well when there is a low prevalence of cases. Yelin et al. (2020) found that positive samples can still be well observed in pools in up to 32 samples, and possibly even 64 with additional PCR cycles. However, the detection of positives in a large pool is possible only when viral loads are very high. The viral load presence in COVID-19 patients can vary over more than nine orders of magnitude (Batson et al., 2020) . This can cause a substantial difference in the distributions of Ct values between labs and test populations. Therefore, any lab using batch testing needs to monitor the rate of excess false negatives regularly. In future studies, we will investigate the presence of the dilution effect by focusing on the implementation aspects of the assay such as sampling site, sampling timing, operational consistency of the sampler, and storage of the samples. We will consider implementing a constraint on the batch size as maximum 32 or 64 in our multistep batch procedure. This constraint will increase the number of tests, but it will reduce the dilution effect. We will also investigate optimal stopping rules to further improve the efficiency and efficacy of the multistep batch testing procedure.

Additional supporting information may be found online in the Supporting Information section at the end of the article. 

A two-dimensional YAC pooling strategy for library screening via STS and Alu-PCR methods

Theoretical analysis of library screening using a N-dimensional pooling strategy

A comparison of group testing architectures for COVID-19 testing

Statistical methods for batch screening of input populations by stage and group in COVID-19 nucleic acid testing

The detection of defective members of large populations

Composite sampling approaches for bacillus anthracis surrogate extracted from soil

Sample pooling as a strategy to detect community transmission of SARS-CoV-2

Optimal configuration of a square array group testing algorithm

Group testing with a dilution effect

Frequently asked questions for KCDC on COVID-19 (updated on 24 April). Press Release

Korea considers testing pooled samples for vulnerable groups

Testing on the move: South Korea's rapid response to the COVID-19 pandemic

Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. The Lancet Infectious Diseases

Regression models for group testing data with pool dilution effects

A pooled testing strategy for identifying SARS-CoV-2 at low prevalence

S. Korea to start using pooling methods to test 10 samples at a time

The use of a square array scheme in blood testing

Efficient and practical sample pooling for high-throughput PCR diagnosis of COVID-19

Coronavirus (COVID-19) update: Facilitating diagnostic test availability for asymptomatic testing and sample pooling. Press Announcement, CDRH Offices, US Food and Drug Administration

COVID-19 testing: The threat of false-negative results

False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence

Patients with RT-PCR-confirmed COVID-19 and normal chest CT

Evaluation of COVID-19 RT-qPCR test in multisample pools

Xiaolin Li and Haoran Jiang are supported in part by U.S. Army Research Office grant W911NF-18-10346, Xiaolin Li and Hongshik Ahn are supported by the U.S. Army Research Office through the equipment grant W911NF-20-10159. The authors thank Andrew Ahn for useful discussions and giving valuable comments on a draft of this paper. The authors would like to thank the associate editor and two anonymous reviewers for their thoughtful suggestions and comments, which greatly improved our presentation. The authors do not have a conflict of interest to declare.

The authors have declared no conflict of interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

This article has earned an Open Data badge for making publicly available the digitally-shareable data necessary to reproduce the reported results. The data is available in the Supporting Information section.This article has earned an open data badge "Reproducible Research" for making publicly available the code necessary to reproduce the reported results. The results reported in this article could fully be reproduced.

Ahn https://orcid.org/0000-0002-7706-3320